BioSpace News Archive

Ionis Pharmaceuticals, Inc. announced positive results from an ongoing Phase 2 open-label extension study evaluating the safety and efficacy of its investigational prophylactic medicine, donidalorsen, in patients with hereditary angioedema, a rare and life-threatening genetic disease.

Bayer and US-based Recursion Pharmaceuticals, Inc., a clinical stage TechBio company decoding biology to industrialize drug discovery, announced that they have updated the focus of their research collaboration to precision oncology.

Apyx Medical Corporation reported financial results for its third quarter ended September 30, 2023, and updated its financial expectations for the full year ending December 31, 2023.

GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that Harout Semerjian, Chief Executive Officer, will participate in a fireside chat at the Jefferies London Healthcare Conference in London, UK on Thursday, November 16, 2023 at 1:30 p.m. GMT/8:30 a.m. ET.

Precision BioSciences, Inc. today announced that an abstract featuring preclinical data for its wholly owned PBGENE-HBV program has been accepted for late-breaker presentation at the American Association for the Study of Liver Diseases (AASLD) Annual Meeting being held in Boston, MA on November 10-14, 2023.

Landos Biopharma, Inc. provided a business update and announced financial results for the quarter ended September 30, 2023.

Avalyn Pharma Inc. announced the presentation of preclinical data that supported the completed Phase 1a trial of AP02 as well as clinical data for AP01 at the 2023 Pulmonary Fibrosis Foundation Summit at the JW Marriott Grande Lakes in Orlando, FL.

Recludix Pharma announced that Nancy Whiting, Pharm.D., chief executive officer of Recludix, will present at two investor conferences in November.

Vera Therapeutics, Inc. reported its business highlights and financial results for the third quarter ended September 30, 2023.

Recce Pharmaceuticals Ltd today announced it completed dosing the first healthy subjects at the highest concentration of 3,000mg within a fast infusion rate of 15-minutes in a Phase I/II trial evaluating its lead anti-infective candidate, RECCE® 327 (R327).